Commentary

Video

Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy

Mah previews a packed 2025 Annual Meeting, from the debut of SightLine to Dr. Glaucomflecken’s return to the main stage, and outlines his priorities for the year ahead as incoming ASCRS president.

Francis S. Mah, MD, incoming president of the American Society of Cataract and Refractive Surgery (ASCRS), sat down with the Eye Care Network to share his goals and perspectives ahead of the 2025 ASCRS Annual Meeting, taking place April 25–28 in Los Angeles, California. The role is a 1-year term, and Mah sees it as an opportunity to build on the momentum of past leadership.

“It’s obviously a huge honor,” Mah said, noting the legacy of strong leadership within ASCRS. Following Vance Thompson, MD’s term—which spotlighted the business and practical aspects of ophthalmic care—Mah plans to shift focus slightly. “I’d like to focus again on some of the aspects that really got me interested and excited to participate... such as education, research, the [ASCRS] Foundation, as well as Government Relations.”

Mah emphasized the importance of strengthening ASCRS’ role in an uncertain health care landscape, particularly with evolving FDA policies and the impact on research and industry partnerships. “We need to really try to strengthen those areas that might get impacted,” he said, adding that support for members engaged in research and innovation will be essential.

This year’s conference introduces SightLine, a new meeting held on the day before the Annual Meeting and designed to replace Eyecelerator and refocus on practical challenges in anterior segment surgery. “SightLine really... focuses more on the practice of medicine,” Mah explained, aligning with ASCRS’ mission to deliver timely, practice-enhancing content.

Subspecialty days on Friday will include the Roger Steinert and new Ed Holland named lectures, along with a fresh session on the business of interventional glaucoma surgery. A keynote appearance on Sunday by Dr. Glaucomflecken is also expected to draw wide interest.

“It’s a phenomenal meeting,” Mah said, encouraging colleagues to attend and engage deeply. “Try to absorb as much and really enjoy what ASCRS can provide for you in your everyday practice.”

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.